current and future treatment approaches for hr-mds
Published 2 years ago • 112 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:06
the current state of the art in hr-mds and the need to improve treatment approaches
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:14
an overview of the current and future treatment landscape for mpns
-
0:59
the current challenges facing high-risk mds treatment
-
2:04
state-of-the-art treatment for hr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:21
future treatment priorities for high-risk mds
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
1:35
challenges with diagnosing mds and future outlooks
-
1:13
the main treatment goals in lr-mds and how these differ from hr-mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:29
the current landscape of maintenace therapy in aml and areas for future exploration
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
3:21
an insight into the standard of care in hr-mds and future outlooks
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:16
state of the art: mds
-
1:39
current landscape and future directions for lower-risk mds treatment